Background

Both high on-treatment platelet reactivity and periprocedural myocardial infarction (MI) are associated with adverse events following percutaneous coronary intervention (PCI). The optimal method of quantifying platelet reactivity remains controversial.

Methods

Ninety-eight patients underwent platelet function testing with VerifyNow P2Y12 at 6 to 24 h following PCI. All patients received 600 mg of clopidogrel before PCI; those presenting with acute MI or baseline troponin elevation were excluded. Periprocedural MI was defined as peak troponin >upper limit of normal (0.12 ng/ml); and high on-treatment platelet reactivity (HOPR), as ≥235 platelet reactivity units. Multivariable logistic regression was performed to assess the independent effect of on-treatment platelet reactivity upon peak troponin.

Methods

Ninety-eight patients underwent platelet function testing with VerifyNow P2Y12 at 6 to 24 h following PCI. All patients received 600 mg of clopidogrel before PCI; those presenting with acute MI or baseline troponin elevation were excluded. Periprocedural MI was defined as peak troponin >upper limit of normal (0.12 ng/ml); and high on-treatment platelet reactivity (HOPR), as ≥235 platelet reactivity units. Multivariable logistic regression was performed to assess the independent effect of on-treatment platelet reactivity upon peak troponin.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Coronary stenting with MGuard: extended follow-up of first human trial
2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
3. Treatment of STEMI with neither PCI nor thrombolysis
4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree